National Institute of Allergy and Infectious Diseases (NIAID): Coronavirus Infections trials

The registry lists 20 Coronavirus Infections studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 5 are open to participants now and 7 have results posted.

Phase 1 8Phase 2 2Phase 3 4No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 VaccineNot yet recruitingNCT07703475Phase 1
• A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated AdultsRecruitingNCT07536308Phase 1
• Respiratory Virus Sampling and RepositoryRecruitingNCT05266222
• Observational Digital Biomarker Discovery in Respiratory Virus Challenge StudiesRecruitingNCT04772170
• Viral Infections in Healthy and Immunocompromised HostsRecruitingNCT01306084
• Aviptadil for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedNCT06729606Phase 3Results posted
• Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)CompletedNCT06729593Phase 3Results posted
• Safety Study of SLV213 for the Treatment of COVID-19.TerminatedNCT06146374Phase 1Results posted
• ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19CompletedNCT04843761Phase 3Results posted
• ACTIV-2: A Study for Outpatients With COVID-19CompletedNCT04518410Phase 2/3Results posted
• COVID-19 and Anti-CD14 Treatment TrialTerminatedNCT04391309Phase 2Results posted
• Safety, Tolerability, and Pharmacokinetics of SAB-301 in Healthy AdultsCompletedNCT02788188Phase 1Results posted
• A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular RoutesActive, not recruitingNCT07221162Phase 1
• Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in AdultsCompletedNCT07095231Phase 1
• COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-CCompletedNCT04588363
• A Longitudinal Study of COVID-19 Sequelae and ImmunityActive, not recruitingNCT04411147
• Collection of Anti-SARS-CoV-2 Immune PlasmaCompletedNCT04344977
• A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051CompletedNCT03301090Phase 1
• SARS Coronavirus Vaccine (SARS-CoV)WithdrawnNCT00533741Phase 1
• SARS Survivor EvaluationsWithdrawnNCT00523276